Background: Nocardiosis is a life-threatening opportunistic infection. Solid organ
| INTRODUC TI ON
Nocardia is a gram positive, partially acid-fast aerobic branching filamentous bacteria belonging to the order of actinomycetes. It causes life-threatening opportunistic infection in immunocompromised individuals with a tendency for recurrence. 1 Disseminated nocardiosis has a mortality ranging from 7% to 44%. 1 years, an incidence about 340 times greater than the incidence in the 3 general populations. SOT patients had the highest incidence at 1122 cases/10 5 person years which is about 3000 times greater than that of the general population. 2 Nocardia is ubiquitous in the environment including soil and organic matter. Since a dry and dusty environment promotes aerosolization of micro-organisms, it is unsurprising that the respiratory system is the main point of entry for the Nocardia bacteria into humans. 1 Additionally, this explains why pulmonary involvement is the most common presentation with nocardiosis.
In a study on microbial keratitis by Stapleton et al, 3 Nocardia was found exclusively in temperate climates. 3 Kachuei et al 4 studied diversity and frequency of different species of Nocardia in relation to environmental factors including soil pH in the Isfahan province of Iran. They had a similar observation to Stapleton et al's: most Nocardia species were found in semi-desert, temperate climates. 4 To date, 2 large scale studies on nocardiosis in SOT patients have been conducted; including a European multi-center study by Coussement et al 5 and a single-center study by Peleg et al 6 at the University of Pittsburgh. Peleg et al 6 reported an incidence of 0.6% in their SOT recipients, and Nocardia nova was the most commonly isolated species in their study. Their results suggested that high dose corticosteroids, Cytomegalovirus (CMV) infection, and high median calcineurin inhibitor levels were independent risk factors for the development of Nocardia infection. CMV has immunomodulatory effects, and calcineurin inhibitors inhibit T-cell activation, causing a greater degree of immunosuppression.
Coussement et al 5 identified the length of ICU stay and age in addition to the aforementioned risk factors in Peleg et al's study as an independent risk factors for the development of nocardiosis.
Additionally in their study, Nocardia farcinica was more frequently associated with disseminated disease than other Nocardia species. factors associated with 1-year mortality. They found that history of tumor, invasive fungal infection, and donor age were independently associated with 1-year mortality. Acute transplant rejection in the year before diagnosis was associated with improved survival, probably due to more close monitoring and thus early diagnosis in these patients. Further, they found good outcomes with short antibiotic treatment courses (≤120 days).
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Coussement et al's 5 and Peleg et al's 6 work provided considerable insight into nocardiosis in SOT patients. We conducted a retrospective study of nocardiosis in SOT patients at our center to investigate its incidence and to explore risk factors associated with the development of disseminated disease and mortality. Our secondary aim was to describe the clinical, microbiological, and radiological characteristics of Nocardia infection. To our knowledge, this is the first large study of nocardiosis in SOT recipients in the southwestern United States.
| MATERIAL S AND ME THODS

| Study design and participants
We performed a retrospective review of microbiological and clinical data of adult patients diagnosed with nocardiosis after SOT between 1997 and 2016 at the University of Arizona/Banner University
Medical Center (BUMC). Total of 2038 patients underwent SOT
between 1997 to 2016 at BUMC. A total of 260 adult cases of nocardiosis were identified from microbiology laboratory records.
Patients were included in our study if they met the inclusion criteria outlined below. This resulted in the inclusion of 54 patients. Rest of 206 patients had following risk factors: cystic fibrosis, immunosuppression due to chemotherapy, COPD, malignancy, autoimmune disease, BMT, and HIV.
| Inclusion criteria
To be included in the study, we required patients to have all of the following characteristics: (i) They needed to be a SOT recipient.
(ii) 
| Clinical data
We recorded a wide range of data on study patients. 
| Microbiology
| Statistical analysis
Key variables related to each patient's SOT and nocardiosis diagnosis were recorded in a REDCap database hosted at the University of Arizona for ease of data aggregation and analysis.
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Numeric data were summarized using means, standard deviations, medians, and ranges. Categorical data were summarized using counts and percentages. To explore the association of various risk factors with the development of disseminated disease and mortality, a series of Fisher's exact tests was used. A P-value of <.05
was considered statistically significant. All the data was analyzed 
| RE SULTS
Total of 2038 patients underwent SOT between 1997 and 2016 at BUMC. 260 patients were identified from microbiology laboratory records as having nocardiosis. The data of 54 patients who met the inclusion criteria of nocardiosis after SOT was analyzed. The TA B L E 1 Demographic information, comorbidities, therapeutic characteristics, induction therapy and CMV serostatus of patients 
(9%)
Any missing values stem from question not pertinent to that individual or missing data for those patients. CMV, Cytomegalovirus; D, donor; R, recipient; +, positive; −, neagative.
incidence of nocardiosis among SOT at our institution between 1997 and 2016 was 2.65% (54 out of 2038 SOT patients).
| Patient characteristics
The majority of patients (74%) were male. Nocardiosis occurred at a median age of 58 years (range 19-79). The majority (67%) of patients were white non-Hispanic. Heart was the most commonly transplanted organ with heart transplants taking place in 37% of patients.
Following the heart, the next most commonly transplanted organs were the lung (31%), the kidney (22%), both heart and lung (6%), the liver (2%), and the pancreas (2%). The incidence of Nocardia in different transplanted organs was as follows: lung 9.28%, heart + lung 
| Microbiological, radiological, and therapeutic characteristics
Pulmonary involvement in the Nocardia infection was the most common (76%) followed by CNS plus lung, cutaneous/subcutaneous plus lung, and CNS alone. 13 (24%) patients had disseminated disease.
76% of patients were diagnosed by culture, 13% by pathology, and 11% by combined culture and pathology. In tissue, lungs (79%) were the most common source of culture followed by soft tissue, brain and bone. 81% of Nocardia isolates were speciated. Predominant species All patients underwent chest imaging at the time of diagnosis.
Computed tomography (CT) scan was the most common imaging modality followed by chest-x-ray and MRI. The most common radiological characteristic was consolidation. At our institution, all patients diagnosed withpulmonary Nocardia receive CNS imaging. MRI was performed in 100% of patients diagnosed with CNS nocardiosis.
The most common site of CNS lesions was the cortex. Abscess was the most common radiological impression on CNS imaging. Most patients had a single "rim" enhancing lesion followed by multiple and nodular enhancing lesions.
Antibiotic sensitivities were performed in 61% of isolates. 91%
of Nocardia species on which antibiotic sensitivity testing was performed were sensitive to TMP/SMX. TMP/SMX was included in most treatment regimens. The duration of therapy in 74% of patients was between 1 and 12 months. 11% of patients received therapy between 12 and 24 months, 10% for >24 months and data was missing for 5% patients. Data on therapy duration was missing for 6% of patients. In 63% of patients, the original antibiotic regimen was changed. Regimen simplification and renal failure were the major reasons followed by gastrointestinal side effects, resistance, bone marrow suppression, and treatment failure. One patient (2%) had recurrence of Nocardia infection after treatment was stopped. In 27% of the patients on whom we have this information, TMP/SMX remained the definitive treatment followed by minocycline (24%), minocycline plus moxifloxacin (9%), ceftriaxone (6%), and amoxicillin/clavulanate (6%) (Tables 2-5).
| Risk and protective factors and Nocardiosis development
100% of patients were on immunosuppressive therapy at the time of diagnosis; 93% of patients were on prednisone, 83% on tacrolimus, 70% on mycophenolate, 19% on cyclosporine, and 13% on azathioprine. 52% of patients on whom we had this information had an increase in tacrolimus dose 6 months prior to diagnosis, and 44% of patients on whom we had this information had elevated tacrolimus levels (>20 ng/mL) 6 months prior to diagnosis. 54% of patients taking corticosteroids were on them for >6 months. In 70% of patients, the prednisone dose ranged from over 5-20 mg daily (Table 6 ).
18 (33%) patients had rejection (acute rejection in 5 patients, chronic rejection in 11 and unknown in 2 patients). 60% of patients had acute rejection in the 6 months before diagnosis of nocardiosis (Table 6 ). 11 (20%) patients developed CMV viremia after transplant.
Most common CMV serostatus was donor (+), recipient (−) in 30%, followed by 22% donor (+), recipient (+); 17% donor (−), recipient (−);
9% donor (−), recipient (+) and 22% unknown (Table 1) . Table 6 ). This is somewhat surprising, as we might expect high dose prophylaxis to confer some protection against development of nocardiosis. However, given the lack of a control group, we cannot draw any conclusions about the relationship between TMP/ SMX or the risk factors discussed above and the development of nocardiosis.
| Risk factors for development of disseminated disease
Fisher's exact test revealed no association between the development of disseminated disease and the following variables: transplant rejection (P = 1), elevated tacrolimus levels (P = .4) and CMV viremia (P = .06; Table 7 ).
| Mortality and its risk factors
Overall mortality (death within 1 year of Nocardia diagnosis plus death after 1 year of Nocardia diagnosis) was 17% and 1-year mortality was 11%. 1 patient (2%) likely died due to Nocardia infection as confirmed by autopsy (Table 3 ). Fisher's exact test found no association between mortality (levels alive, died within 1 year, and died after 1 year) and the following variables; disseminated disease (P = .1593), type of transplant (P = .5171), transplant rejection (P = .1561), CMV viremia (P = .3714), and renal failure (P = 1). T-tests comparing ages in (i) the group of patients that died within 1 year and the group that did not die within 1 year and (ii) the group of patients that died and the group of patients that did not die, found no association between mortality and age (P = .9 and P = .5, respectively; Tables 8 and 9 ). Any missing values stem from question not pertinent to that individual or missing data for those patients. CNS, central nervous system; CT, computed topography scan; MRI, magnetic resonance imaging. a CNS (brain/spinal cord/meninges). b Skin (Cutaneous/Subcutaneous, including abscess).
TA B L E 2 Chest, CNS Imaging and organs involved by nocardiosis
TA B L E 3 Diagnostic modalities, clinical signs, and mortality
Characteristic Summary information (%)
Method of diagnosis 
1-year mortality 6 (11)
Mortality due to Nocardia infection 1 (2)
Any missing values stem from question not pertinent to that individual or missing data for those patients.
| D ISCUSS I ON
We have reported results from the first large scale study on nocardiosis in SOT patients in the southwestern US. We described the incidence of nocardiosis in SOT patients, their microbiological, radiological and clinical characteristics and evaluated risk factors for disseminated disease and mortality.
Incidence of Nocardia in SOT patients between 1997 and 2006
at our center was 2.65%. This is much higher than what has been reported in either Peleg et al 6 or Coussement et al 5 The incidence of Nocardia in SOT patients was reported as 0.6% in Peleg et al 6 On personal request, Coussement et al 5 reported the incidence at one of their centers to be 0.13% in kidney transplant patients and 1.2% in heart transplant patients. The differences between the incidence of nocardiosis in these studies and at our center could be due to the environmental influences reported by Kachuei 4 and Stapleton.
3 Studies of the relationship between ecology and climatology and nocardiosis would be helpful in determining whether or not environmental factors in the southwestern US influence the development of nocardiosis.
The incidence of Nocardia has largely been reported in liver, kidney, and heart transplant recipients. [12] [13] [14] [15] The incidence in lung transplant recipients has been published in only a few case reports, a case series and one large scale study. [16] [17] [18] In our study, the incidence was found to be highest (9.28%) in lung transplant recipients. To our knowledge, this is the highest incidence ever reported in these patients. For comparison, Peleg et al 6 also reported the highest incidence in lung transplant recipients, but this incidence was 3.5%.
One probable explanation for such high incidence in lung transplant recipients could be their higher degree of immunosuppression, the pulmonary route of transmission in nocardiosis, and decreased muco-ciliary clearance in lung transplant patients.
Species identification and determining its prevalence is important
because it helps guide empiric antibiotic therapy. Nocardia asteroides used to be the most frequently isolated pathogen until the end of 1990s. 19 In Coussement et al, 5 Nocardia farcinia and Nocardia nova were the most commonly isolated species. Peleg et al 6 reported
Nocardia nova as their most predominant species. In our study Nocardia farcinica had the highest incidence, but Nocardia Cyriacigeorgia and Peleg et al 6 reported CMV viremia as an independent risk factor for development of Nocardia (P = .047, OR 6.9). In contrast, CMV viremia was not significantly associated with the development of Nocardia in Coussement et al's 5 study (P = .18). In our study due to the lack of a control group, we cannot calculate the association of CMV viremia with the development of nocardiosis. However, we reported CMV viremia was not significantly associated with disseminated nocardiosis. Moreover, 91% of Nocardia isolates tested were TMP/SMX sensitive.
TA B L E 4 Antibiotic susceptibility testing of Nocardia spp. Antibiotic susceptibility testing was performed in 33 (61%) patients In line with Coussement et al's hypothesis; it could be that despite the TMP/SMX sensitivity, even stronger doses than those in our study are needed to help prevent nocardiosis. However, it should again be noted that our lack of control group does not allow us to evaluate the role of TMP/SMX prophylaxis in nocardiosis. Further studies are needed to continue exploring the relationship between high dose TMP/SMX prophylaxis and the development of nocardiosis in high-risk patients.
Disseminated nocardiosis is a fatal disease with mortality rate >85% in immunocompromised hosts if left untreated. 11 Identifying risk factors for disseminated nocardiosis would help in early diagnosis and management and thus alleviate the mortality rate. None of the variables we tested (transplant rejection, elevated tacrolimus levels and CMV viremia) were associated with disseminated disease.
Although the P-value for CMV viremia was borderline, it did not reach statistical significance.
Despite the higher incidence of nocardiosis in the Southwest Furthermore, the relapse rate was also lower (2% in our population vs 6% in Coussement et al 5 ). This could be due to early diagnosis as Any missing values stem from question not pertinent to that individual or missing data for those patients. DS, double strength; TMP/SMX, trimethoprim-sulfamethoxazole.
TA B L E 5 (Continued)
of deaths might explain the lack of association between mortality and factors we evaluated (disseminated disease, type of transplant, transplant rejection, CMV viremia and renal failure). It was also not possible to evaluate and compare with other studies the role of potential risk factors that had not been recorded in the medical records of our patients.
In conclusion, the incidence of nocardiosis is high in the Southwestern US possibly due to the arid environment. Perhaps unsurprisingly given the ease of the respiratory infection route, the highest incidence was in our lung transplant patients.
Additionally, many of our patients were on steroids and calci- Interestingly, a large number of our patients (17 out of total 46 who received TMP/SMX) were on a double strength daily dose of TMP/SMX, thus calling its possibly protective effects against Nocardia development into question. This needs to be studied further. Surprisingly, none of risk factors we tested were found to be associated with dissemination or mortality. Given our small sample size and the limited number of deaths, this needs to be explored in future work.
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